August 24, 2023 03:38 PM EDTUpdated 03:48 PM
Pharma
FDA+

CMS’ Medicare ne­go­ti­a­tion list is com­ing next week. Here’s what to ex­pect

Nicole DeFeudis

Editor

Lia DeGroot

The clock is tick­ing as phar­ma com­pa­nies wait to see what 10 Medicare Part D drugs will be up for the first round of price …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Sage sues Bio­gen days af­ter $469M buy­out of­fer

FDA ap­proves As­traZeneca and Dai­ichi Sankyo’s ADC for breast can­cer de­spite lack of sur­vival ben­e­fit

Ozem­pic makes list for next round of Medicare drug price ne­go­ti­a­tions

Roche's car­diometa­bol­ic chief warns against weight loss 'ob­ses­sion' with GLP-1s

What Trump's CMS can and can't change with the sec­ond round of drug price ne­go­ti­a­tions

#JPM25 live blog day 1: How will Trump 2.0 im­pact the bio­phar­ma in­dus­try? Scott Got­tlieb, Bob Nelsen share ...

A service from the Financial Times